MDT

86.81

+0.25%↑

121.23

+2.1%↑

VEEV

167.91

-0.62%↓

HQY

86.23

+2.35%↑

NEOG

9.59

+2.79%↑

MDT

86.81

+0.25%↑

121.23

+2.1%↑

VEEV

167.91

-0.62%↓

HQY

86.23

+2.35%↑

NEOG

9.59

+2.79%↑

MDT

86.81

+0.25%↑

121.23

+2.1%↑

VEEV

167.91

-0.62%↓

HQY

86.23

+2.35%↑

NEOG

9.59

+2.79%↑

MDT

86.81

+0.25%↑

121.23

+2.1%↑

VEEV

167.91

-0.62%↓

HQY

86.23

+2.35%↑

NEOG

9.59

+2.79%↑

MDT

86.81

+0.25%↑

121.23

+2.1%↑

VEEV

167.91

-0.62%↓

HQY

86.23

+2.35%↑

NEOG

9.59

+2.79%↑

Home・Lista de Ações・Denali Therapeutics Inc

Denali Therapeutics Inc

Abrir

SetorSaúde

21.09 1.54

Comprar Vender

Visão Geral

Variação de preço das ações

24h

Atual

Mín

20.57

Máximo

21.34

Indicadores-chave
By Trading Economics
Rendimento	-1.6M -129M
Funcionários	503
EBITDA	8.9M -125M

Recomendações
By TipRanks
Recomendações	Compra Forte
Previsão para 12 meses	+75.13% upside

Dividendos
By Dow Jones
Próximos Ganhos	4 de mai. de 2026

Estatísticas de Mercado
By TradingEconomics
Capitalização de Mercado	-178M 3.1B
Abertura anterior	19.55
Fecho anterior	21.09

Sentimento de Notícias

By Acuity

50%

162 / 348 Ranking em Healthcare

Pontuação Técnica

By Trading Central

Confiança

Strong Bearish Evidence

13.355 / 16.44 Suporte e Resistência

Denali Therapeutics Inc Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

16 de abr. de 2026, 23:26 UTC

Ações em Alta

Stocks to Watch: Netflix, Alcoa, Knight-Swift, NiSource

16 de abr. de 2026, 20:41 UTC

Grandes Movimentos do Mercado

Netflix Shares Slide After 2Q Outlook Misses Wall Street's Expectations

16 de abr. de 2026, 23:49 UTC

Conversa de Mercado

Amplitude's Pivot to Oil-Linked Supply Deal Catches Bull's Eye -- Market Talk

16 de abr. de 2026, 23:45 UTC

Conversa de Mercado

Nikkei May Decline After Hitting Record High -- Market Talk

16 de abr. de 2026, 23:33 UTC

Conversa de Mercado

Notícias Principais

Gold Edges Higher on Hopes for U.S.-Iran Deal -- Market Talk

16 de abr. de 2026, 22:51 UTC

Conversa de Mercado

Netflix Sees Signs That Podcasts May Boost Engagement -- Market Talk

16 de abr. de 2026, 22:08 UTC

Ganhos

Netflix Chair Reed Hastings to Leave Board in June -- 3rd Update

16 de abr. de 2026, 22:06 UTC

Ganhos

Lundin Mining: Earnings From Discontinued Ops in 1Q Expected to Be Positively Impacted by Unaudited Gain on Disposal of Eagle Mine, Totaling Approximately $4M >LUN.T

16 de abr. de 2026, 22:06 UTC

Ganhos

Lundin Mining: Pre-Announces Items Impacting 1Q Results

16 de abr. de 2026, 22:06 UTC

Ganhos

Lundin Mining: Items of Significant Impact in 1Q Expected to Include Unaudited Realized Losses on Derivative Contracts of Approximately $13M, Primarily Related to Gold Collar Contracts >LUN.T

16 de abr. de 2026, 22:06 UTC

Ganhos

Lundin Mining: Rev in 1Q Expected to Be Positively Impacted by Unaudited Provisional Pricing Adjustments on Prior-Period Concentrate Sales of Approximately $22M on Pre-Tax Basis >LUN.T

16 de abr. de 2026, 22:06 UTC

Ganhos

Lundin Mining: Adjustments Primarily Include Upward Adjustments in Relation to Prior-Period Metal Sales >LUN.T

16 de abr. de 2026, 20:50 UTC

Conversa de Mercado

Ganhos

Tech, Media & Telecom Roundup: Market Talk

16 de abr. de 2026, 20:50 UTC

Conversa de Mercado

Financial Services Roundup: Market Talk

16 de abr. de 2026, 20:50 UTC

Conversa de Mercado

Notícias Principais

Basic Materials Roundup: Market Talk

16 de abr. de 2026, 20:50 UTC

Conversa de Mercado

Ganhos

Health Care Roundup: Market Talk

16 de abr. de 2026, 20:49 UTC

Ganhos

SpaceX Is Ready to Go Public. The Stock Market Is Its Rocket. -- Barrons.com

16 de abr. de 2026, 20:43 UTC

Ganhos

Update: Netflix Stock Falls on Weak Guidance. Founder Reed Hastings Is Leaving the Board. -- Barrons.com

16 de abr. de 2026, 20:40 UTC

Conversa de Mercado

Ganhos

Global Equities Roundup: Market Talk

16 de abr. de 2026, 20:40 UTC

Conversa de Mercado

Ganhos

Netflix Says Engagement Quality Hits New High -- Market Talk

16 de abr. de 2026, 20:30 UTC

Ações em Alta

Stocks to Watch: TSMC, Abbott Laboratories, Nvidia, Netflix -- WSJ

16 de abr. de 2026, 20:25 UTC

Ganhos

Netflix Stock Falls on Weak Guidance. Founder Reed Hastings Is Leaving the Board. -- Barrons.com

16 de abr. de 2026, 20:23 UTC

Ganhos

These Stocks Are Today's Movers: AMD, Intel, TSMC, Abbott, Hims, Corning, Schwab, Polaris, and More -- Barrons.com

16 de abr. de 2026, 20:19 UTC

Ganhos

Netflix Guidance Disappoints. The Stock Is Down. -- Barrons.com

16 de abr. de 2026, 20:17 UTC

Ganhos

Alcoa: Alumina Costs in the Aluminum Segment Are Expected to Be Favorable by Approximately $20M Sequentially >AA

16 de abr. de 2026, 20:17 UTC

Ganhos

Alcoa: Based on Higher LME and Midwest Premium Pricing and Expected Higher Shipments, Section 232 Tariff Costs on U.S. Imports of Aluminum From Canada Expected to Increase $35M Sequentially >AA

16 de abr. de 2026, 20:16 UTC

Ganhos

Alcoa: Expects 2026 Total Aluminum Segment Production and Shipments Ranging Between 2.4M and 2.6M Metric Tons, and Between 2.6M and 2.8M Metric Tons, Respectively >AA

16 de abr. de 2026, 20:16 UTC

Ganhos

Alcoa: Expects 2026 Total Aluminum Segment Production and Shipments to Remain Unchanged From Its Prior Projection >AA

16 de abr. de 2026, 20:16 UTC

Ganhos

Alcoa: Expects 2026 Total Alumina Segment Production and Shipments Ranging Between 9.7M to 9.9M Metric Tons, and Between 11.8M and 12.0M Metric Tons, Respectively >AA

16 de abr. de 2026, 20:16 UTC

Ganhos

Alcoa: Expects 2026 Total Alumina Segment Production and Shipments to Remain Unchanged From Prior Projection >AA

Comparação entre Pares

Variação de preço

Denali Therapeutics Inc Previsão

Preço-alvo

By TipRanks

75.13% parte superior

Previsão para 12 meses

Média 36.27 USD 75.13%

Máximo 42 USD

Mínimo 30 USD

Com base em 14 analistas de Wall Street que oferecem metas de preço de 12 meses para Denali Therapeutics Inc - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Compra Forte

14 ratings

Comprar

Manter

Vender

Com base em 14 analistas que deram avaliações de ações para Denali Therapeutics Inc - Dist nos últimos 3 meses.

Pontuação Técnica

By Trading Central

13.355 / 16.44Suporte e Resistência

Recent bearish events outweigh bullish events.

The bullish and bearish events are balanced.

All events are bearish.

Sentimento

By Acuity

162 / 348 Ranking em Saúde

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

Sobre Denali Therapeutics Inc

Denali Therapeutics Inc., a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company's transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2. Its brain-penetrant small molecule programs comprise BIIB122/DNL151 LRRK2 inhibitor program for Parkinson's disease; SAR443820/DNL788 RIPK1 inhibitor program for CNS disease; DNL343 eIF2B Activator program for amyotrophic lateral sclerosis; and SAR443122/DNL758 RIPK1 inhibitor program for peripheral inflammatory diseases. It also provides early stage program include TAK-594/DNL593 program for FTD-GRN; DNL126 program for MPS IIIA, a Sanfilippo Syndrome A; DNL622 for MPS I which is Hurler syndrome; Antibody Transport Vehicle Amyloid beta program; Oligonucleotide Transport Vehicle platform, a novel class of biotherapeutics to address the root cause of diseases through modulation of gene expression; and other TV-enabled discovery programs. The company has collaboration agreements with Biogen MA Inc. and Biogen International GmbH; Genzyme Corporation; Takeda Pharmaceutical Company Limited; F-star Gamma Limited, F-star Biotechnologische Forschungs-und Entwicklungsges m.b.H, and F-star Biotechnology Limited; and Genentech, Inc. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California.